Status:
COMPLETED
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Lead Sponsor:
Bayer
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Eligibility Criteria
Inclusion
- Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1
Exclusion
- Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial.
Key Trial Info
Start Date :
March 12 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2019
Estimated Enrollment :
396 Patients enrolled
Trial Details
Trial ID
NCT00863681
Start Date
March 12 2009
End Date
August 19 2019
Last Update
November 7 2023
Active Locations (99)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles, California, United States, 90073
2
Sacramento, California, United States, 95817
3
Aurora, Colorado, United States, 80045
4
Boston, Massachusetts, United States, 02111